Inhibitors of P38 Map Kinase
AssigneeChroma Therapeutics Ltd.
InventorsDavid Festus Charles Moffat, Stephen John Davies, Stephane Pintat
Life of this patent
Estimating the term…
Loading patent…
AssigneeChroma Therapeutics Ltd.
InventorsDavid Festus Charles Moffat, Stephen John Davies, Stephane Pintat
Estimating the term…
Compounds of formula (I) are p38 MAP kinase inhibitors useful for the treatment of autoimmune and inflammatory diseases: wherein: G is —N═ or —CH═; D is an optionally substituted divalent mono- or bi-cyclic aryl or heteroaryl radical having 5-13 ring members; R6 is hydrogen or optionally substituted CrC3 alkyl; P represents hydrogen and U represents a radical of formula (IA); or U represents hydrogen and P represents a radical of formula (IA); wherein A represents an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members; z is O or 1; —X1-L1-Y— is a linker radical or bond; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; and R2 and R3 are as defined in the claims.
A compound of formula (I):
(canceled)
Dependencies are inferred from the claim text.